FLIP is a potential anti-cancer therapeutic target that inhibits apoptosis by blocking caspase 8 activation by death receptors. We report a novel interaction between FLIP and the DNA repair protein Ku70 that regulates FLIP protein stability by inhibiting its polyubiquitination. Furthermore, we found that the histone deacetylase (HDAC) inhibitor Vorinostat (SAHA) enhances the acetylation of Ku70, thereby disrupting the FLIP/Ku70 complex and triggering FLIP polyubiquitination and degradation by the proteasome. Using in vitro and in vivo colorectal cancer models, we further demonstrated that SAHA-induced apoptosis is dependant on FLIP downregulation and caspase 8 activation. In addition, an HDAC6-specific inhibitor Tubacin recapitulated the effects of SAHA, suggesting that HDAC6 is a key regulator of Ku70 acetylation and FLIP protein stability. Thus, HDAC inhibitors with anti-HDAC6 activity act as efficient post-transcriptional suppressors of FLIP expression and may, therefore, effectively act as 'FLIP inhibitors'. Cell Death and Differentiation (2012) 19, 1317-1327 doi:10.1038/cdd.2012 published online 10 February 2012 FLIP is an anti-apoptotic protein that blocks the activation of apoptosis mediated by death receptors, such as Fas, TRAIL receptor 1 (TRAIL-R1/DR4) and TRAIL-R2 (DR5).
FLIP is an anti-apoptotic protein that blocks the activation of apoptosis mediated by death receptors, such as Fas, TRAIL receptor 1 (TRAIL-R1/DR4) and TRAIL-R2 (DR5).
1 By binding to the adaptor protein FADD, FLIP inhibits apoptosis by blocking the processing and activation of procaspase 8 (FLICE) by death receptor complexes termed DISCs (death-inducing signalling complexes). 2 We previously reported that FLIP inhibits apoptosis induced by chemotherapeutic agents 3 and that high FLIP expression is an independent adverse prognostic biomarker in colorectal cancer (CRC). 4 These and other studies have indicated that inhibition of FLIP constitutes a promising therapeutic strategy for the treatment of CRC. Ku70 and its binding partner Ku80 are critical components of the non-homologous end joining (NHEJ) DNA repair machinery. 5 Ku70 is regulated by acetylation, which is mediated by the histone acetyl transferases (HATs); CREBbinding protein (CBP) and PCAF, and its acetylation can be enhanced by treating cells with histone deacetylase (HDAC) inhibitors. 6 Ku70 acetylation disrupts its DNA-binding activity and sensitises cells to DNA-damaging agents. 7 In addition, cytoplasmic Ku70 binds to and regulates the pro-apoptotic Bcl-2 family member, Bax. 6 Ku70 simultaneously inhibits Bax degradation via the ubiquitin proteasome system (UPS) and prevents its translocation to the mitochondria. 8 Moreover, it has been reported that Ku70 may have intrinsic deubiquitinating (DUB) activity. 8 The Ku70-Bax complex is disrupted by Ku70 acetylation, which promotes Bax translocation to mitochondria and apoptosis induction. 6 Herein, we report a novel interaction between FLIP and Ku70 that regulates FLIP stability. This interaction is acetylation-dependant and is disrupted by HDAC inhibitors with activity against HDAC6. Disruption of the Ku70-FLIP interaction subsequently leads to FLIP degradation by the UPS and induction of caspase 8-dependant apoptosis.
Results
FLIP interacts with Ku70. A yeast-2-hybrid screen was carried out to identify novel binding partners for the long FLIP splice variant (FLIP(L)). One of the novel proteins identified was Ku70. The interaction between FLIP(L) and Ku70 was confirmed by re-transformation assay ( Figure 1a) . Immunoprecipitation experiments confirmed that FLIP(L) interacts with Ku70 in CRC cells (Figure 1b) . Despite the predominant site of Ku70 expression being nuclear, the interaction between FLIP(L) and Ku70 was more prominent in cytosolic fractions (Figure 1c) , suggesting that the primary site of the interaction is cytosolic. Ku70 also interacted with the short FLIP splice form, FLIP(S) (Supplementary Figure S1A) . To map Ku70's interaction with FLIP, we generated a series of Flag-tagged Ku70 constructs. The region from 430 to 609 amino acids interacted strongly with FLIP, however, neither the 496-609 nor the 535-609 fragments interacted ( Figure 1d ). These mapping experiments indicate that Ku70 binds FLIP via a region between amino acids 430 and 496, which encompasses one of its sites of interaction with Ku80.
Ku70 binds to DED2 of FLIP. To identify the regions of FLIP that are important for the FLIP-Ku70 interaction, we used a FLIP peptide array of overlapping 25-mer peptides, each shifted by four amino acids, encompassing the entire FLIP(S) sequence. 9 Duplicate membranes were overlaid with lysates from cells transfected with Flag-Ku70, and the Flag epitope detected by immunoblotting. Strong binding of Ku70 to the array was detected in four regions (Figure 2a and  table) . To map the FLIP-Ku70 interaction to specific amino acids, alanine substitution arrays were constructed for peptides 17, 30, 41 and 46. Several alanine substitutions in peptide 30 (but not the other 3 peptides) were found to disrupt the binding of Ku70 (Figure 2b ). By using viral FLIP MC159 as a template, 10 a homology model of human FLIP(S) was generated. The model predicted that two of the candidate residues identified in the alanine substitution array, Y119 and R122, are prominently surface exposed and, therefore, available for making protein-protein interactions ( Figure 2c) ; the other candidate residues were predicted to be buried. Mutation of FLIP(S) R122, but not Y119, to alanine significantly diminished binding to Ku70 (Figure 2d) . Thus, these studies identify R122 as a critical site of interaction between FLIP and Ku70. This region of FLIP death effector domain 2 (DED2) is present in all FLIP splice forms and is adjacent to the 'hydrophobic patch' region reported to be important for binding to FADD. 11 Binding of FADD and procaspase 8 to FLIP was unaffected by R122A mutation indicating that FADD/procaspase 8 and Ku70 interact with distinct regions of FLIP (Figure 2d ).
SAHA disrupts the FLIP-Ku70 interaction and induces FLIP degradation. Treatment with the HDAC inhibitor Vorinostat (SAHA, suberoylanilide hydroxamic acid) for 2 h disrupted the interaction between endogenous FLIP and Ku70 (Figure 3a) , and increased Ku70 acetylation after 1 h (Figure 3b ). Increased Ku70 acetylation following SAHA treatment was also observed in three other CRC cell lines (Supplementary Figure S1B) . Although Ku70 was primarily expressed in the nucleus, acetylated Ku70 was detectable at similar levels in the nucleus and the cytosol, and increased in both sub-cellular locations following SAHA treatment (Supplementary Figure S1C) . We were unable to detect the acetylation of FLIP following SAHA treatment (Supplementary Figure S1D) , suggesting that it is not directly modified by acetylation. Ku70 acetylation following SAHA treatment decreased its capacity to bind to FLIP (Figure 3b) . Cohen et al. 6 demonstrated that mimicking the acetylation of lysine residues K539 or K542 in Ku70 by mutating them to glutamine disrupted its ability to inhibit Bax-mediated apoptosis. We found that mutation of either of these residues to glutamine impaired the ability of Ku70 to interact with FLIP (Figure 3d ) and rapid downregulation of both splice forms from B4 h following treatment (Figure 3e ). SAHA treatment also downregulated FLIP protein expression in three other CRC cell lines after 6 h at sub-IC50 doses (Supplementary Figures S2C and E) . In contrast to other studies, which have found that HDAC inhibitors downregulate FLIP at the transcriptional level, 12, 13 we found no evidence of transcriptional suppression of FLIP in CRC cells ( Supplementary  Figures S2A and D) . Moreover, co-treatment with the proteasome inhibitor MG132 attenuated SAHA-induced FLIP downregulation (Supplementary Figure S2B) , providing further evidence that FLIP downregulation is mediated by the UPS. Figure S3A) . The FLIP downregulation observed in Ku70-depleted cells was not an indirect result of caspase activation, as inhibition of apoptosis with the pan-caspase inhibitor z-VAD-fmk failed to prevent FLIP downregulation in Ku70-depleted cells (Figure 4d) . Furthermore, the half-lives of both FLIP(L) and FLIP(S) were significantly reduced in Ku70-depleted cells, with almost undetectable levels of FLIP 1 h after treatment with the protein synthesis inhibitor cycloheximide (Figure 4f ). Importantly, Ku70 downregulation resulted in increased levels of polyubiquitinated FLIP(L) and FLIP(S) (Figure 4g ), suggesting that Ku70 enhances the half-life of FLIP by inhibiting its degradation via the UPS.
SAHA-and Ku70 siRNA-induced apoptosis is caspase 8-dependant. Analysis of other apoptotic proteins indicated that unlike FLIP, none were significantly affected by SAHA treatment after 6 h, however, Bax was upregulated and XIAP downregulated 24 h following SAHA treatment (Figure 5a ). Despite being acetylated, total Ku70 expression was not Figures S5A-D) . These results establish direct evidence for FLIP downregulation as a major mechanism of apoptosis induction by SAHA alone and in combination with other anti-cancer agents. Ku70 siRNA- To assess the importance of FLIP downregulation for the in vivo effects of SAHA, we used the FL17 FLIP(L)-overexpressing model. In both parental and FL17 xenografts, treatment with SAHA resulted in increased acetylation of histone H4, a marker of HDAC inhibition (Figure 6d ). SAHA treatment resulted in potent FLIP(L) downregulation in the parental xenografts and also decreased FLIP(L) expression in the FL17 xenografts. However, the levels of FLIP(L) expression that were maintained in SAHA-treated FL17 tumours were comparable to those in vehicle-treated parental xenografts. Notably, SAHA treatment failed to inhibit the growth of FL17 xenografts, whereas the growth of the parental xenografts was significantly inhibited by SAHA (Figure 6e) . These results are the first to demonstrate that SAHA downregulates FLIP in vivo and that FLIP downregulation is important for its anti-tumour activity.
Inhibitors with anti-HDAC6 activity regulate FLIP expression and Ku70 acetylation. To identify the HDACs involved in regulating Ku70 acetylation, we used the HDAC inhibitor Droxinostat, 14 which, although less potent, has a more restricted activity than SAHA: Droxinostat is an inhibitor of HDACs 6 and 8, and (to a lesser extent) HDAC3; 14 SAHA inhibits HDACs 1, 2, 3, 6 and (to a lesser extent) 8.
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In agreement with earlier studies, 16 we found that Droxinostat potently downregulated FLIP expression and did so at early (6 h) time points post-treatment (Supplementary Figure S6A) . However, unlike these earlier studies, we found that this downregulation was post-transcriptional, as this agent had no effect on FLIP mRNA expression (Supplementary Figure  S6B) . Droxinostat-induced apoptosis correlated with FLIP downregulation (Supplementary Figure S6C) , and FLIP downregulation was not caspase dependant (Supplementary Figure S6D) . Like SAHA, Droxinostat-induced apoptosis was caspase 8-dependant (Supplementary Figures S6D and 7A) . Using a 'caspase-trap' assay, 17 we demonstrated that caspase 8 rather than caspase 9 was the first caspase activated in HCT116 cells in response to treatment with both SAHA and Droxinostat for 4 h (Figure 7b ). In addition, Droxinostat-induced apoptosis was inhibited in FL17 cells (Figures 7c and d) . Given the reported importance of Bax for HDAC inhibitor-induced apoptosis, 6 it was notable that the inhibitory effects of caspase 8 silencing or FLIP overexpression on HDAC inhibitor-induced apoptosis were more profound than loss of Bax (Figures 7a and d) . Furthermore, in contrast to a previous study, 18 we found that HDAC inhibitorinduced apoptosis was not p53-dependant in HCT116 cells (Figure 7d ). We previously reported that apoptosis induction following siRNA-mediated FLIP silencing is primarily driven by the TRAIL receptor DR5. 3 In agreement with this, SAHA-and Droxinostat-induced cell death were both significantly attenuated when DR5 was silenced, and this effect was further enhanced when DR4 was co-silenced with DR5 ( Figure 7e) .
As Droxinostat and SAHA both inhibit HDAC6, we hypothesised that HDAC6 may be involved in regulating FLIP expression. To test this, we used an HDAC6-selective inhibitor Tubacin. 19 Both Tubacin and Droxinostat increased Ku70 acetylation to the same extent as SAHA (Figure 8a Entinostat, which inhibits HDACs 1-3, but not HDAC6, 15 was significantly less than that induced by the other HDAC inhibitors (Figure 8a ). In addition, siRNA-mediated depletion of HDAC6 resulted in significantly increased Ku70 acetylation (Figure 8b ). Like SAHA and Droxinostat, Tubacin treatment resulted in rapid FLIP protein downregulation (Figure 8c ), but had no significant effect on FLIP mRNA expression (Figure 8d) . Tubacin also caused an increase in acetylation Figure 7 The HDAC3, 6 and 8 inhibitor downregulates FLIP expression. (a) HCT116 parental and Bax-null cells were transfected with 10 nM SC or caspase 8-targeted (siCasp8) siRNAs for 24 h followed by treatment with 1 mM SAHA or 30 mM Droxinostat (Drox) for a further 24 h. Apoptosis was determined by flow cytometry by assessing the percentage of propidium iodide-stained cells in the sub-G0/G1 apoptotic fraction. (b) HCT116 cells were pre-incubated in the presence of 50 mM biotinylated VAD-fmk for 2 h and then treated with either 10 ng/ml TRAIL, 30 mM Droxinostat or 1 mM SAHA and cultured for a further 4 h. Cells were then lysed and active caspases precipitated using streptavidin-agarose and identified by immunoblotting using specific caspase antibodies. (c) HCT116 parental and FLIP(L) overexpressing (FL17) cells were treated with 10, 30 and 60 mM Droxinostat (Drox) for 24 h, and the resulting cell lysates were separated by SDS-PAGE and immunoblotted for FLIP(L) and FLIP(S). (d) HCT116 parental, Bax-null, p53-null and FL17 cells were treated with 1 mM SAHA or 30 mM Drox for 24 h, and apoptosis was determined by flow cytometry by assessing the percentage of propidium iodide-stained cells in the sub-G0/G1 apoptotic fraction. (e) HCT116 parental cells were transfected with 10 nM control (SC), DR4-or DR5-targeted siRNAs for 24 h followed by treatment with 1 mM SAHA or 30 mM Drox for a further 24 h. Apoptosis was determined by flow cytometry by assessing the percentage of propidium iodide-stained cells in the sub-G0/G1 apoptotic fraction (ns, not significant; *Po0.05; **Po0.01; ***Po0.001; Student's t-test) of a-tubulin, a marker of HDAC6 inhibition, whereas acetylation of histone H4, a marker of nuclear HDAC inhibition, was significantly lower following Tubacin treatment than following SAHA treatment (Figure 8c ). In contrast, Entinostat failed to downregulate FLIP expression in HCT116 cells after 6 h at a concentration that potently increased acetylation of histone H4, but had no effect on acetylation of a-tubulin (Figure 8e ). In addition, Tubacin-induced apoptosis was highly FLIPdependant as determined by flow cytometry (Figure 8f ), consistent with FLIP downregulation being a primary mechanism of apoptosis induction in response to this agent.
Discussion
We previously demonstrated that FLIP is an important regulator of apoptosis induction and drug resistance in CRC. 3, 20 We carried out a yeast-2-hybrid screen to identify novel FLIP-interacting proteins, with the aim of identifying novel regulators of FLIP expression or function. This screen identified Ku70, a DNA repair protein that was initially characterised as being critical for NHEJ. 21 Ku70 was subsequently shown to have an apoptosis-regulating function through its ability to bind to and sequester Bax. 6 Both the DNA-and Bax-binding activities of Ku70 are acetylation dependant. 6, 7 Acetylation of Ku70 at residues K539 and K542 in its C-terminus by CBP and PCAF disrupt its ability to inhibit Bax-mediated apoptosis. 6 Moreover, Ku70 was reported to have intrinsic DUB activity that inhibits Bax degradation via the UPS. 8 We found that FLIP interacts with Ku70 via a region in the DED2, using a site (R122) adjacent to the region that is functionally important for FLIP binding to FADD. 11 Binding of FADD and procaspase 8 to FLIP was unaffected by mutation of R122, indicating that Ku70 interacts with a region of FLIP that is distinct from the region with which it interacts with these DISC components. Furthermore, Ku70 did not bind to FLIP via the same region it binds Bax, but rather via a region previously shown to be important for dimerisation with Ku80 (amino acids 430-496). 22 Therefore, FLIP interacts with the same region of Ku70 with which it engages Ku80 and does so using a region in DED2 not involved in its DISC recruitment. In addition, fractionation experiments suggested that similar to Bax, the primary sub-cellular location of the FLIP-Ku70 interaction is cytoplasmic.
Ku70 depletion resulted in significant decreases in FLIP expression. Furthermore, the decrease in FLIP expression following Ku70 silencing was because of a decrease in protein stability. Treatment with the HDAC inhibitor SAHA resulted in the acetylation of Ku70 and disrupted its interaction with FLIP. Moreover, mimicking Ku70 acetylation by mutating the residues K539 and K542 to glutamine resulted in reduced Ku70-FLIP binding. These lysine residues are present in the flexible C-terminal linker region adjacent to the region of Ku70, which binds FLIP (amino acids 430-496). It is possible that acetylation of this flexible linker region causes a conformational change of Ku70 that disrupts binding of FLIP in the adjacent 430-496 region, or that acetylation disrupts binding of an as yet unidentified binding partner (or partners) that is important for maintaining the Ku70-FLIP complex.
Although we found no evidence of FLIP acetylation following SAHA treatment, polyubiquitination of both FLIP(L) and FLIP(S) was increased, and both splice forms were rapidly downregulated in a proteasome-dependant manner. A direct link between Ku70 and FLIP ubiquitination status was indicated by the increased levels of polyubiquitinated FLIP(L) and FLIP(S) in Ku70-silenced cells. In contrast to numerous other studies, 12, 13 we found no evidence that SAHA downregulated FLIP expression at the transcriptional level. However, our findings agree with a recent study in breast cancer models, which also found that SAHA-induced FLIP downregulation was post-transcriptional. 23 In addition, a related pan-HDAC inhibitor Panobinostat (LBH589) was recently reported to cause FLIP polyubiquitination and proteasomal degradation in pancreatic cancer cells. 24 Collectively, these findings suggest that SAHA causes Ku70 acetylation, resulting in the disruption of its interaction with FLIP leading to degradation of FLIP by the UPS.
Although Ku70 is a substrate for the HATs CBP and PCAF, 6 the HDACs that regulate Ku70 acetylation have not been previously characterised. In this study, we provide evidence that HDAC6 is a key deacetylase for Ku70 as, in addition to Vorinostat (inhibitor of HDAC1-3, 6 and 8) 15 and Droxinostat (inhibitor of HDAC3, 6 and 8), 14 the HDAC6-specific inhibitor Tubacin 19 potently increased the acetylation of Ku70. Moreover, both Droxinostat and Tubacin also caused rapid FLIP downregulation. In contrast, Entinostat, which inhibits HDAC1-3, but has no activity against HDAC6, 15 failed to downregulate FLIP at early time points and had less impact on Ku70 acetylation. During revision of this manuscript, another study was published that also found that HDAC6 deacetylates Ku70. 25 HDAC6 is a unique HDAC that has key roles in regulating protein turnover by the proteasome through its regulation of HSP90 and by the aggresome through its ability to recruit polyubiquitinated proteins to the tubulin cytoskeleton. 26 Thus, this study identifies a further potential role for HDAC6 in regulating protein stability through its ability to deacetylate Ku70, thereby stabilising FLIP. By deacetylating Ku70, HDAC6 may also regulate Bax and possibly other as yet unidentified Ku70-binding partners.
Although a number of studies have shown that HDAC inhibitor-mediated downregulation of FLIP sensitises various cancer cell lines to death ligands, such as TRAIL, 23, 27, 28 to our knowledge, no previous studies have directly examined whether FLIP downregulation is a sufficient death signal for apoptosis induction when these agents are administered as single agents. We found that FLIP downregulation in response to HDAC inhibitors results in caspase 8-and DR5-mediated apoptosis, phenocopying the mechanism of apoptosis that we previously observed in CRC cells following siRNA-mediated downregulation of FLIP. 3 We also demonstrate for the first time that SAHA downregulates FLIP in vivo and that FLIP(L) overexpression abrogates SAHA's in vivo anti-tumour activity. FLIP(L) overexpression or caspase 8 downregulation had a greater inhibitory effect on HDAC inhibitor-induced apoptosis than loss of Bax, suggesting that the extrinsic apoptotic pathway is at least as important as the intrinsic pathway in mediating the effects of HDAC inhibitors in CRC cells.
From a cancer therapeutics perspective, these results suggest that HDAC inhibitors with anti-HDAC6 activity act as efficient post-transcriptional suppressors of FLIP expression in CRC. HDAC inhibitors are promising anti-cancer therapeutics that have demonstrated pre-clinical and clinical activities in haematological and solid cancers, and SAHA was the first of this class of compound to be FDA approved. [29] [30] [31] [32] [33] There have been several early phase clinical trials in advanced, chemotherapy-resistant CRC examining SAHA in combination with standard 5-Fluorouracil (5-FU)-based chemotherapy. [34] [35] [36] In one of these studies, 21/38 5-FU-refractory patients had stable disease and 1 had a partial response. 34 The plasma concentrations of SAHA achieved in these patients were similar to the concentrations that we find are sufficient to downregulate FLIP. Of note, we found that SAHA synergized with both 5-FU and oxaliplatin to induce apoptosis in CRC cells; however, this synergy was abolished in cells overexpressing FLIP(L). Thus, FLIP and components of the extrinsic pathway, such as caspase 8, may be useful predictive biomarkers for the targeted use of HDAC inhibitors in CRC.
In conclusion, we provide evidence that Ku70 regulates FLIP ubiquitination and that HDAC inhibitor-mediated acetylation of Ku70 disrupts the interaction between FLIP and Ku70 resulting in degradation of FLIP via the UPS and induction of caspase 8-dependant apoptosis (summarised in Figure 9 ).
Materials and Methods
Reagents. The following reagents were used: Vorinostat (Zolinza, SAHA; Selleck Chemicals, Suffolk, UK); Droxinostat (4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide, compound #5809354) and its inactive analogue 4-(4-chloro-2-methylphenoxy)-N-(3-ethoxypropyl)butanamide (compound #7271570, ChemBridge Corporation, San Diego, CA, USA). Tubacin was a kind gift from Dr. Ralph Mazitschek and Dr Stuart Schreiber (Howard Hughes Medical Institute, Broad Institute of Harvard and MIT). Entinostat (MS-275) was synthesised in the laboratory as previously described. 37, 38 Cycloheximide and MG132 (Sigma-Aldrich, Dorset, UK). Biotinylated z-VAD-fmk (Val-Ala-Asp-CH2F) and immobilised Streptavidin slurry were purchased from MP Biomedicals (Cambridge, UK) and Thermo Fisher Scientific (Leicestershire, UK), respectively.
Cell culture. HCT116, H630, HT29 and RKO human CRC cell lines were used as previously described. 3, 39 Matched isogenic p53 and Bax-null HCT116 cell lines 
